Table 4 Duration of nephrotic syndrome, steroid therapy, laboratory, and echocardiographic data in cases with diastolic dysfunction dysfunction vs. cases without

Serum creatinine at the time of assessment (mg/dL)

0.79 ± 0.04

0.8 ± 0.04

0.44

Serum urea at the time of assessment (mg/dL)

14 ± 1.9

12 ± 3.1

0.65

Serum baseline cholesterol (mg/dL)

229 ± 11

231 ± 10

0.43

Serum cholesterol at the time of assessment (mg/dL)

175 ± 193

175 ± 19

0.78

Serum baseline albumin (gm/dL)

2.1 ± 0.2

2.2 ± 0.2

0.59

Serum albumin at the time of assessement (gm/dL)

2.4 ± 0.2

2.8 ± 0.1

< 0.001

Baseline urine P/C ratio

6 ± 0.8

5.2 ± 0.5

0.68

Urine P/C ratio at the time of assessment

2.9 ± 0.6

1.5 ± 0.3

< 0.001

Duration from onset of NS to time of assessment by echocardiography (weeks)

14.9 ± 2

15.9 ± 1

0.07

Duration of steroid therapy (weeks)

15 ± 2

12 ± 1

0.44

Dose of steroid

2 ± 0

2 ± 0

0.78

Weight difference from the onset to time of assessment (kg)

2.3 ± 0.3

3.1 ± 0.3

< 0.001

3D LVEDV (ml)

60 ± 8

59 ± 13

0.42

3D EF (%)

78 ± 2.5

79 ± 3.1

0.33

FS (%)

46 ± 3

46 ±2

0.39

GLS (%)

15 ± 3.2

19 ± 1.41

< 0.0001

E/e′

13±3

8±2

< 0.0001